Illumina stock
Price history
+66.35% over the period1 year: from $120.08 (November 17, 2025) to $199.75 (November 16, 2026), +66.35%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $199.75 |
| October 30, 2026 | $235.99 |
| September 30, 2026 | $273.68 |
| August 31, 2026 | $213.63 |
| July 31, 2026 | $205.10 |
| June 30, 2026 | $175.83 |
| May 29, 2026 | $162.96 |
| April 30, 2026 | $126.74 |
| March 31, 2026 | $123.26 |
| February 27, 2026 | $134.46 |
| January 30, 2026 | $144.81 |
| December 31, 2025 | $131.16 |
| November 28, 2025 | $131.45 |
| November 17, 2025 | $120.08 |
At a glance
The company
Provide sequencing and array-based solutions for genetic and genomic analysis, serving research centers, academic institutions, hospitals and diagnostic laboratories
Latest results
Quarter to September 30, 2026 · EPS $1.44 (estimate $1.36)
TickerLandia's take on Illumina
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 37 vs a median of 48 over its last 7 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 36 vs 36 (+0%) in a group of 9.
- Strong point: Market momentum (86/100 in its group). Weak point: Earnings stability (7/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−35.43% from the 52-week high
Analysts · 21 analysts
Average target$261.45+30.89% vs. price
Buy 10 · Hold 7 · Sell 4 · Buy
TickerLandia Fingerprint: Illumina
Compared with similar companies: very low earnings stability and very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh74
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 36.1 52 Price/sales 6.90 72 EV/EBITDA 28.3 78 Forward P/E 33.5 90 Price/book 10.0 79 Profitabilityhigh77
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 67.7% 91 Net margin 19.7% 83 ROE 32.4% 83 ROA 8.3% 72 Operating margin 19.1% 57 Earnings stabilityvery low7
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 41.2% 2 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 13 Growthaverage43
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −1.78% 17 Earnings growth (year over year) +45.90% 87 Revenue growth (year over year) +4.20% 24 Financial strengthhigh62
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.00 70 Debt/equitycounts in reverse: lower means more financial strength 0.74 39 Interest coverage 8.60 60 Current ratio 2.63 80 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong86
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +15.32% 81 1-year return +72.61% 95 Relative strength (6 months) +40.55% 92 Relative strength (3 months) +10.83% 75 Riskhigh69
How much the price swings.
Metric Value Position in group Volatility (60 days) 69.3% 90 Beta (1 year) 1.10 67 Maximum drawdown (12 months) 29.5% 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Illumina is cheaper than in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Illumina's P/E today is 36.7, below the median of its last 7 fiscal years (48.0; between 24.8 and 80.9 from 2016 to 2025). Illumina's P/E (trailing 12 months): 36.1, in line with the median of a group of 9 similar companies (36.1).
Compared with 9 similar companies
| Metric | Illumina | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 36.1 | Middle | |
| Forward P/E | 33.5 | Middle | |
| Operating margin | 19.1% | Middle | |
| ROE | 32.4% | Middle | |
| Debt/equity | 0.74 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Illumina. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.16B
Latest quarter · Q2 2026
Net income
$207M
Latest quarter · Q2 2026
Quarterly net margin
17.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $31.3B
- P/E
- 36.1
- EPS
- $5.74
- Volume
- 1.23M
- Daily trading
- €488.21M
How Illumina is changing
All resultsRevenue grew 6.0% a year on average over the last 5 years
Operating margin rose from −91.2% to 18.6%
Shares outstanding up 5.4% in 5 years
Returns
Illumina returns with dividends
$1,000 invested in Illumina 5 years ago, on November 16, 2021, would be worth $543 today: −45.75% in total, −11.51% per year. This is the price return only: dividends are excluded.
| Period | Illumina | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −23.92% | −3.12% | $761 |
| 6 months | +40.14% | +2.07% | $1,401 |
| Year to date | +52.29% | +10.46% | $1,523 |
| 1 year | +66.35% | +13.33% | $1,663 |
| 3 years | +121.79% | +67.73% | $2,218 |
| 5 years | −45.75% | +60.86% | $543 |
| 10 years | +52.25% | +247.35% | $1,523 |
Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Illumina: technical analysis
Illumina shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 60.9% below its all-time closing high ($510.54, August 16, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 33
- Between 30 and 70
- vs 200-session average
- +11.10%
Support and resistance
Price areas where Illumina has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$199.75
- Support$198.33−0.71%2 touches, last on September 11, 2026
- Support$178.05−10.86%2 touches, last on July 21, 2026
- Support$154.05−22.88%5 touches, last on June 17, 2026
Volatility and risk
Over the last year it has moved roughly in line with the S&P 500.
- Beta (1 year) vs S&P 500
- 1.10
- Volatility (60 sessions, annualised)
- 69.4%
- Largest fall in the last year
- −31.99%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Illumina: seasonality
Average monthly price change over 27 years
Over the last 27 years, the strongest month for Illumina has been January: +9.22% on average, positive in 18 years out of 26. The weakest has been February: −4.50% on average, positive in 9 years out of 26. November, the current month, has been positive in 15 years out of 26 (+1.13% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +9.22% | +5.84% | 18 of 26 |
| February | −4.50% | −2.10% | 9 of 26 |
| March | −0.10% | +1.45% | 14 of 26 |
| April | +1.72% | +0.86% | 16 of 26 |
| May | +4.85% | +1.15% | 15 of 26 |
| June | +4.48% | +4.63% | 19 of 26 |
| July | +2.26% | +3.09% | 18 of 26 |
| August | −0.33% | −2.48% | 12 of 27 |
| September | +0.88% | −0.75% | 13 of 27 |
| October | +2.32% | +3.01% | 15 of 27 |
| November | +1.13% | +2.04% | 15 of 26 |
| December | +2.92% | +3.10% | 16 of 26 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Illumina and its competitors
The Americas generate the largest share of revenue, 55.4% of the total in the fiscal year ended December 2025, followed by Europe at 29.1%, Asia Pacific, the Middle East and Africa at 9.9%, and China at 5.6%. The company develops sequencing and array platforms for genomic analysis, with instruments and consumables such as reagents, flow cells and library preparation kits. Its whole-genome and targeted resequencing kits cover entire genomes, exomes, specific genes and RNA regions.
- Headquarters
- San Diego, United States
- Employees
- 8,600
- Founded
- 1998
- Chief executive
- Jacob Thaysen
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| IlluminaILMN | $31.3B | 19.1% | 36.1 | +40.14% |
| Labcorp HoldingsLH | $30.08B | 11.2% | 30.4 | +48.09% |
| Quest DiagnosticsDGX | $28.56B | 14.9% | 25.9 | +40.23% |
| Mettler-Toledo InternationalMTD | $34.59B | 27.8% | 37.7 | +67.76% |
| IQVIA HoldingsIQV | $43.36B | 13.9% | 32.0 | +56.42% |
| NateraNTRA | $46.27B | -8.5% | — | +56.81% |
Same industry or related industries, similar size. Compare Illumina with its competitors · Full profile
